Medtronic’s EPS of $1.39 exceeded the Zacks Consensus Estimate, showcasing strong financial performance.
The company’s revenue reached approximately $8.29 billion, with significant growth in the cardiovascular and diabetes segments.
Despite a slight decline in shares, Medtronic maintains a positive annual profit forecast, indicating a focus on long-term stability.
Medtronic plc (NYSE: MDT) is a global leader in medical technology, services, and solutions. The company operates in various segments, including cardiovascular, diabetes, and minimally invasive therapies. Medtronic’s competitors include companies like Boston Scientific and Abbott Laboratories. On February 18, 2025, Medtronic reported earnings per share (EPS) of $1.39, surpassing the estimated $1.36, showcasing its strong financial performance.
The company’s revenue for the quarter was approximately $8.29 billion, slightly below the estimated $8.33 billion. Despite this, Medtronic’s earnings per share of $1.39 exceeded the Zacks Consensus Estimate of $1.36, marking an improvement from the previous year’s $1.30 per share. This growth was driven by robust demand for its heart and diabetes devices, as highlighted by Zacks.
Medtronic’s cardiovascular segment saw a 3.7% increase in sales, reaching $3.04 billion, meeting market expectations. The diabetes segment experienced an 8.4% growth, generating $694 million, surpassing the anticipated $681.8 million. These results reflect the company’s strong market position and ability to meet consumer demand in key areas.
Despite the strong performance, Medtronic’s shares experienced a 1.4% decline, dropping to $91.49 in premarket trading. The company maintained its annual profit forecast in the range of $5.44 to $5.50 per share, aligning closely with analysts’ average estimate of $5.45. This cautious approach indicates Medtronic’s focus on long-term stability and growth.
Medtronic’s financial metrics provide insights into its valuation and financial health. With a price-to-earnings (P/E) ratio of approximately 27.76 and a price-to-sales ratio of about 3.61, the company is valued favorably by investors. The debt-to-equity ratio of 0.58 and a current ratio of 1.84 suggest a moderate level of debt and a solid ability to cover short-term liabilities.
